Press Release

  View printer-friendly version
<< Back
Dextera Surgical’s MicroCutter 5/80™ and Cardiac Anastomotic Devices to Be Featured at the 31st Annual European Association for Cardio-Thoracic Surgery

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 9, 2017-- Dextera Surgical Inc. (Nasdaq: DXTR), a company developing and commercializing the MicroCutter 5/80™ Stapler, today announced that several leading surgeons will feature the use of Dextera Surgical’s MicroCutter 5/80™ Stapler and its C-Port® Distal Anastomosis Systems in three oral presentations at the 31st Annual European Association for Cardio-Thoracic Surgery. The meeting is taking place in Vienna, AustriaOctober 7-11, 2017.

“We are extremely pleased to have both the MicroCutter and the C-Port Systems highlighted in key presentations at EACTS, the largest cardiothoracic surgery meeting in the world,” said Liam Burns, vice president global sales and marketing of Dextera Surgical. “We believe our presence at this important meeting, for the fourth year in a row, validates the procedure-enabling nature of the MicroCutter in uniportal approaches as well as the C-Port System’s integral role during totally endoscopic coronary artery bypass procedures.”

MicroCutter 5/80 Presentations

Davor Stamenovic, M.D., of St. Vincentius Hospital in Karlsruhe, Germany will give two oral presentations highlighting the uses of the Microcutter 5/80 during single-port video-assisted thoracic surgery (VATS) procedures. The presentations will be as follows:

  • Tuesday, October 10 at 4:56 p.m. local time
    Posterior uniportal video-assisted surgery for anatomical lung resection
  • Wednesday, October 11 at 9:50 a.m. local time
    Uniportal video-assisted thoracoscopic anatomical left upper lobe anterior (S3) segmentectomy

Dr. Stamenovic commented, “During lung procedures through a single incision, space for surgical tools is at a premium. The slim profile of the MicroCutter 5/80 provides critical visibility of the targeted anatomy and the increased angulation enables near perpendicular transection of the blood vessels. Neither the visibility nor the articulation provided by the MicroCutter 5/80 is available in any alternative stapling device.”

Cardiac Presentation

Husam H. Balkhy, M.D., of the University of Chicago Medicine, presented the results of 265 totally endoscopic coronary artery bypass (TECAB) procedures at his hospital.

  • Sunday, October 8 at 2:48 p.m. local time
    Robotic totally endoscopic coronary bypass with distal connectors: Mid-term outcomes at a single academic institution with an experienced team

“I am excited to present the results from 265 patients who have undergone robotic bypass procedures over the course of the last 3.5 years at a single academic institution,” said Dr. Balkhy. “The data highlight significant improvement in patient outcomes defined by shorter hospital stay and the ability to return to their normal daily routine much more rapidly when compared to open heart surgery. I believe studies like this are driving an increasing interest in learning how to perform robotic procedures among my fellow cardiac surgeons. Importantly, a critical tool for TECAB procedure success is the C-Port Distal Anastomosis System, the only available automated anastomosis tool, which reliably connects the graft to the coronary artery making the totally endoscopic procedural approach possible.”

MicroCutter Indication Information

The MicroCutter 5/80 Stapler and MicroCutter 30 White, Blue and Curved Tip White and Blue Reloads are intended for transection and resection in multiple open or minimally invasive urologic, thoracic, and pediatric surgical procedures, as well as application for transection, resection, and/or creation of anastomoses in the small and large intestine, and the transection of the appendix. The MicroCutter 5/80 Stapler and MicroCutter 30 White and Curved Tip White Reloads may additionally be used in conjunction with open solid organ parenchymal dissection techniques on veins four to five millimeters in diameter and arteries three to seven millimeters in diameter.

About the C-Port® Distal Anastomosis Systems (C-Port systems)

In the United States, the C-Port Systems are intended for use in the creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures. The C-Port systems – the C-Port xA system and the Flex-A® system – can be used on- or off-pump and create compliant anastomoses that expand and contract with blood flow. The C-Port systems work on coronary arteries as small as 1.3 millimeters in internal diameter and work with grafts of various diameters and vessels with single wall thicknesses less than 0.75 millimeters. The Flex-A system allows surgeons to position the device to create a secure connection even in difficult to reach areas of the heart.

About Dextera Surgical

Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.

Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.

Forward-Looking Statements

The statements in this press release regarding the beneficial use of the MicroCutter 5/80 and C-Port® Distal Anastomosis System are "forward-looking statements." There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including Dextera’s need for additional funding, complications in the manufacturing process may not be resolved in a timely manner, and the other risks detailed from time to time in Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, under the caption “Risk Factors.” Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.

Source: Dextera Surgical Inc.

Dextera Surgical Inc.
Bob Newell, 650-331-7133
Vice President, Finance and Chief Financial Officer
investors@dexterasurgical.com